EMERGENT BIOSOLUTIONS INC. Operating Expenses
EMERGENT BIOSOLUTIONS INC. (EBS) reported Operating Expenses of $991.90 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2020-02-25
- EMERGENT BIOSOLUTIONS INC. operating expenses for the quarter ending 2019-12-31 was $282.60M, a 8.90% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. operating expenses for the quarter ending 2019-09-30 was $241.10M, a 58.31% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. operating expenses for the quarter ending 2019-06-30 was $250.20M, a 63.10% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. operating expenses for the quarter ending 2019-03-31 was $217.80M, a 71.09% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. operating expenses for fiscal 2019 was $991.90M, a 43.21% increase from fiscal 2018.
- EMERGENT BIOSOLUTIONS INC. operating expenses for fiscal 2018 was $692.60M, a 58.63% increase from fiscal 2017.
- EMERGENT BIOSOLUTIONS INC. operating expenses for fiscal 2017 was $436.60M, a 13.91% increase from fiscal 2016.
- EMERGENT BIOSOLUTIONS INC. operating expenses for fiscal 2016 was $383.30M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2019-12-31 | $282.60M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $523.70M derived: sum of 2 quarters · filed 2020-02-25 | $773.90M derived: sum of 3 quarters · filed 2020-02-25 | $991.90M 10-K · filed 2020-02-25 |
| 2019-09-30 | $241.10M 10-Q · filed 2019-11-07 | $491.30M derived: sum of 2 quarters · filed 2019-11-07 | $709.30M 10-Q · filed 2019-11-07 | $968.60M derived: sum of 4 quarters · filed 2020-02-25 |
| 2019-06-30 | $250.20M 10-Q · filed 2019-08-02 | $468.30M 10-Q · filed 2019-08-02 | $727.50M derived: sum of 3 quarters · filed 2020-02-25 | $879.80M derived: sum of 4 quarters · filed 2020-02-25 |
| 2019-03-31 | $217.80M 10-Q · filed 2019-05-08 | $477.30M derived: sum of 2 quarters · filed 2020-02-25 | $629.60M derived: sum of 3 quarters · filed 2020-02-25 | $783.00M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-12-31 | $259.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $411.80M derived: sum of 2 quarters · filed 2020-02-25 | $565.20M derived: sum of 3 quarters · filed 2020-02-25 | $692.60M 10-K · filed 2020-02-25 |
| 2018-09-30 | $152.30M 10-Q · filed 2019-11-07 | $305.70M derived: sum of 2 quarters · filed 2019-11-07 | $433.10M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $153.40M 10-Q · filed 2019-08-02 | $280.70M 10-Q · filed 2019-08-02 | ||
| 2018-03-31 | $127.30M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $436.60M 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $383.30M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |